Eltrombopag, a new drug, has been registered
Mir-Pharm announces successful registration of new orphan drug
Moscow, November 2023
The drug Eltrombopag contains the active substance eltrombopag, which belongs to the group of drugs that stimulate hematopoiesis. It is used to increase low platelet levels in liver disease and immune thrombocytopenia (ITP). It increases the number of platelets in the blood. By doing this, the risk of bleeding is reduced. It can also be used to treat aplastic anemia, a condition that occurs when there is insufficient production of new blood cells.
Note:
The press release contains information about prescription medications. Use of this information for preparation of publications must be made in accordance with the legislation of the Russian Federation on advertising (including but not limited to Art. 24 of the Federal Law of 13.03.2006 No. 38-FL "On Advertising"), according to which, in particular, advertising of prescription drugs is allowed only in places of medical or pharmaceutical exhibitions, workshops, conferences and other similar events as well as in specialized print media intended for medical and pharmaceutical workers. Failure to comply with the above requirements (namely, mentioning the name of the drug, placing an image of the package or its elements in the media other than specialized print publications intended for medical and pharmaceutical workers) shall entail administrative liability.